US pharmaceutical giant Pfizer reported Tuesday that third-quarter profit more than doubled as strength in newer drugs to treat cancer and other illnesses offset the hit from patent expirations.

Net income came in at $2.8 billion, compared with just under $1.4 billion in the year-ago period, a quarter that was hit with one-time expenses connected to Pfizer acquisitions.